Keynote speakers

Matthew Vander Heiden (Cambridge, MA, USA)
Michael Murphy (Cambridge, UK)
Jose Enriquez (Madrid, Spain)

Speakers

Mike Berridge; Malaghan Institute of Medical Research, Wellington, New Zealand
Ravi Sachidanandam; School of Medicine at Mount Sinai, New York, USA
Boris Zhivotovsky; Karolinska University, Stockholm, Sweden and Lomonosov State University, Moscow, Russia
Shazib Pervaiz; National Singapore University, Singapore
Jean-Claude Martinou; University of Geneva, Switzerland
Christoph Borner; University of Freiburg, Germany
Joseph T. Opferman; St Jude Children's Research Hospital, Memphis, TN, USA
Boris Turk; Jozef Stefan Institute, Ljubljana, Slovenia
Alan Prem Kumar; National Singapore University, Singapore
Tomas Mracek; Institute of Physiology, Prague, Czech Republic
Ildiko Szabo; University of Padova, Italy
Jakub Rohlena; Institute of Biotechnology, Prague, Czech Republic
Paulo Oliveira; University of Coimbra, Portugal
Miria Ricchetti; Pasteur Institute, Paris, France
Daret St Clair; University of Lexington, KY, USA
Catherine Brenner; University of Paris Sud, France
Karel Pacak; NIH, Bethesda, MD, USA
Stepana Boukalova; Institute of Biotechnology, Czech Republic
Sona Hubackova; Institute of Biotechnology, Czech Republic
Michelangelo Campanella; University College London, UK
Gianmario Sambucetti; University of Genoa, Italy
Jared Rutter; University of Utah, Salt Lake City, UT, USA
Thomas Simmen; University of Alberta, Edmonton, Canada
Kaye Truscott; La Trobe University, Melbourne, Australia
Shu-Huei Kao; Taipei Medical University, Taiwan
Jaroslav Truksa, Institute of Biotechnology, Czech Republic
Thomas Simmen, University of Alberta, Canada
Cristina Ugalde, Hospital of October 12, Madrid, Spain
Sunghyouk Park, Seoul National University, Korea
Gary Cecchini, University of California, San Francisco, CA, USA
Vladimir Gogvadze, Karolinska Institute, Stockholm, Sweden
Jiri Neuzi, Institute of Biotechnology, Prague, Czech Republic
Barbara Souza, University of Porto, Portugal
Markus Keller, University of Innsbruck, Austria
Anne-Marie Rodriguez, University Paris-Sud, Creteile, France
Luigi Leanza, University of Padova, Italy
Hans Zischka, Helmholz Centre, Munich, Germany
Julius Lukes, Institute of Parasitology, Ceske Budejovice, Czech Republic

Conference Programme

Day 1 - Tuesday, September 17
Time Chair Presenter Title
15.00Registration opens
16.50-17.00Conference opening
17.00-18.00J. Neuzil M. Vander Heiden, Cambridge, USA KT1 Metabolic limitations of cancer progression
18.30-22.00Welcome reception
Day 2 - Wednesday, September 18
Time Chair Presenter Title
9.00-10.45 S. Pervaiz
J. Rohlena
Session 1: Metabolic Remodeling and Mitochondria
9.00 J.-C. Martinou
Geneva, CHI
PT1 Mitochondrial RNA granules: physical properties and role in mitochondrial gene expression
9.30 B. Turk
Ljubljana, SLO
LT1 Extracellular cysteine cathepsins: targets for diagnostics and therapy in cancer
9.50 M. Keller
Innsbruck, A
LT2 Phospholipid acyl chain diversity controls the tissue-specific assembly of mitochondrial cardiolipins
10.10 S.-H. Kao
Taipei, RC
LT3 Mitochondrial translocation of estrogen receptor ß affords resistance to oxidative insult-induced apoptosis and contributes to the pathogenesis of endometriosis
10.30 M. Tomasetti
Ancona, I
ST1 MiRNAs in cancer mitochondrial reprogramming: miR-126-induced metabolic changes as new therapeutic target
10.45-11.15 Coffee Break
11.15-13.05 P. Oliveira
A. Pecinova
Session 2: Role of Tumour Environment in Cancer
11.15 M. Campanella
London, GB
LT4 Mitochondria form contact sites with the nucleus to couple pro-survival retrograde response in cancer cells
11.35 L. Leanza
Padova, I
LT5 Impaired mitochondrial ATP production downregulates Wnt signaling via ER stress induction
11.55 M. Ricchetti
Paris, F
LT6 Mitochondrial defects in an accelerated ageing syndrome and regular ageing cells
12.15 B. Sousa
Porto, P
LT7 The anti-oxidant activity of P-cadherin promotes metastasis and doxorubicin resistance in breast cancer
12.35 S. Hubackova
Prague, CZ
ST2 Simultaneous targeting of dihydroorotate dehydrogenase and cell cycle checkpoints suppresses tumor progression
12.50 HPST/Agilent
Prague, CZ
CP A deep look into the living cells: Agilent/HPST metabolomic solution
13.05-14.00 Lunch break
Optional commercial presentation (20min)
Michaela Pluskalova, HPST, Agilent and Nanolive distributor:
Real-Time Quantification of ATP Production Rate & Direct Mitochondrial Imaging
14.00-15.35 M. Murphy
S. Boukalova
Session 3: Mitochondrial Metabolism in Cancer
14.00 D. StClair
Lexington, USA
LT8 Targeting mitochondrial ROS: Two birds with one stone?
14.20 P. Oliveira
Coimbra, P
LT9 Mitochondria, pluripotency and quality control in embryonal carcinoma cells
14.40 S. Park
Seoul, ROK
LT10 Mitochondrial pyruvate metabolism assessed by NMR live metabolomics
15.00 S. Herkenne
Padova, I
LT11 Developmental and tumor angiogenesis requires changes in endothelial cell mitochondria-shaping protein Opa1
15.20 J. Starkova
Prague, CZ
ST3 Mechanism of action of L-asparaginase: separate roles of asparagine and glutamine in its cytostatic effect
15.35 G. Rigoni
Padova, I
ST4 Dissecting the dual role of ATAD3A in nucleoids stability and cristae ultrastructure
15.50-16.10 Coffee Break
16.10-18.00 M. Berridge
J. Starkova
Session 4: Mitochondria-Associated Membranes and Miscellaneous
16.10 T. Simmen
Edmonton, CDN
LT12 Mechanisms allowing for adaptation of the mitochondria-associated membrane (MAM) in cancer
16.30 G. Sambucetti
Genoa, I
LT13 Uptake of 18F-fluoro-deoxyglucose (FDG) as an index of NADPH generation within the endoplasmic reticulum
16.50 W. StClair
Lexington, USA
LT14 The RelB-BLNK axis is a novel determinant of cellular responses to radiation therapy
17.10 C. Gibhardt
Gottingen, D
LT15 ER-mitochondria contacts affect melanoma progression via redox signals
17.30 C. Cardenas
Santiago, CHI
ST5 Cancer cells with defective oxidative phosphorylation require endoplasmic reticulum-to-mitochondria Ca2+ transfer for survival
17.45 D. Schatton
Cologne, D
ST6 The role of the CLUH/astrin/kinastrin complex in mitochondrial biogenesis
18.00-20.00 Poster Viewing + Drinks/Finger Food
Video presentation: 3D& Label - free, a new paradigm in live cell imaging?
20.00 Departure to Hotel Occidental
Day 3 - Thursday, September 19
Time Chair Presenter Title
9.00-11.05 S.-H. Kao
P. Dolezal
Session 5: Horizontal Transfer of Mitochondria
9.00 M. Sachidanandam
New York, USA
LT16 Heteroplasmy: ubiquitous, stable and unique?
9.20 M. Berridge
Wellington, NZ
LT17 The presence of mitochondrial DNA controls immune responses in a metastatic breast cancer model
9.40 A.-M. Rodriguez
Creteil, F
LT18 Mitochondria from dying cells activate the cytoprotective function of mesenchymal stem cells through a heme oxygenase-1- dependent mechanism
10.00 J. Rohlena
Prague, CZ
LT19 Respiratory function in proliferating and quiescent cells: de novo pyrimidine synthesis versus maintenance of autophagy
10.20 A. Campalans
Paris, F
ST7 Instability of the human mitochondrial genome: a matter of G's?
10.35 V. Henrichs
Prague, CZ
ST8 Mitochondria-adaptor TRAK enables kinesin-1 driven transport in crowded environments
10.50 R. Quintana-Cabrera
Salamanca, E
ST9 Connexin 43 impacts exogenous mitochondrial acquisition by glioblastoma cells
11.05-11.30 Coffee Break
11.30-13.00 I. Szabo
L. Andera
Session 6: Bcl-2 Proteins and Metabolism
11.30 S. Pervaiz
Singapore, SGP
LT20 Active Rac-1 is implicated in redox-dependent pro-survival activity of serine 70 phosphorylated Bcl-2
11.50 C. Brenner
Paris, F
LT21 Identification of cardiac glycosides for prevention of anti-cancer treatment-induced cardiotoxicity
12.10 C.-F. Sin
Hong-Kong, HK
ST10 Arsenic trioxide is effective in treating T-ALL and synergistic effect when combined with ruxolitinib
12.30 R. Rodriguez
Memphis, USA
ST11 Mitochondrial structure and cristae architecture control by Mic60
12.45 J. Mistry
Norwich, GB
ST12 Superoxide drives PI3K kinase mediated mitochondria transfer from the bone marrow microenvironment to hematopoietic stem cells in response to infection
13.00-14.00 Lunch Break
Optional commercial presentation (20 min)
Jitka Zrostlikova, HPST, Agilent distributor: Give biological context to your data:
Agilent metabolomics workflows
13.30-15.10 Session 7: Mitocans I
14.00 J. Opferman
Memphis, USA
PT2 Modulation of the heme pathway for improving the efficacy of BH3 mimetic agents in poor prognosis leukemia
14.30 J. Neuzil
Prague, CZ/Qld, AUS
LT22 Mitochondrially targeted tamoxifen as an anti-cancer agent: From the bench to the bedside
14.50 I. Szabo
Padova, I
LT23 Killing chemoresistant leukemia cells by targeting a mitochondrial potassium channel
15.10-15.30 Coffee Break
15.30-16.40 Session 8: Non-Apoptotic Cell Death Pathways
15.30 C. Borner
Freiburg, D
PT3 Apoptosis induced by Herpes Simplex Virus-1 (HSV-1) involves both Puma- and NF?B-regulated mechanisms
16.00 B. Zhivotovsky
Stockholm, S
LT24 Involvement of mitochondria in the regulation of mitotic catastrophe
16.20 H. Zischka
Munich, D
LT25 Mitochondria are indispensable for liver cancer cell proliferation
16.40-17.00 Coffee Break
17.00-18.00J. Enriquez M. Murphy
Cambridge, GB
KT2 Mitochondrial metabolite signalling in health and disease
18.00-sharp! Coach departure for dinner
19.00-22.00 Steamer boat conference dinner
Day 4 - Friday, September 20
Time Chair Presenter Title
9.00-10.25 L. Leanza
K. Vanova
Session 9: Evolutionary aspects of mitochondria and Mitocans II
9.00 J. Lukes
C. Budejovice, CZ
PT4 The surprisingly complex mitochondrial proteomes of protists
9.30 P. Dolezal
Prague, CZ
LT26 Ensnared dynamics of miniature mitochondrial organelles
9.50 J. Truksa
Prague, CZ
LT27 Mitochondrial iron chelation impairs FeS cluster biogenesis, induces mitophagy and triggers cell death in cancer cells
10.10 S. Boukalova
Prague, CZ
ST13 SMAD4 loss decreases oxidative metabolism in pancreatic cancer and modulates sensitivity to mitochondrial therapy
10.25-10.45 Coffee Break
10.25-12.30 S. Park
S. Hubackova
Session 10: Mitochondrial Respiration and Cancer
10.25 K. Pacak
Bethesda, USA
PT5 New treatment options for metastatic pheochromocytoma and paraganglioma
10.55 G. Cecchini
San Francisco, USA
LT28 Structure and catalytic properties of a human signaling assembly intermediate of complex II of the mitochondrial respiratory chain
11.15 K. Truscott
Melbourne, AUS
LT29 Assembly of human respiratory complex II
11.35 C. Ugalde
Madrid, E
LT30 Multiple pathways regulate respirasome biosynthesis and stabilization
11.55 T. Mracek
Prague, CZ
LT31 TMEM70 facilitates biogenesis of mammalian ATP synthase by promoting subunit c incorporation into the rotor structure of the enzyme
12.15 K. Vanova
Prague, CZ
ST14 Mitochondrial complex II integrity in tumorogenesis
12.30-13.00 Coffee Break + finger food
13.00-14.00M. Vander Heiden J. Enriquez
Madrid, E
KT3 TBA
14.00-14.15 J. Neuzil
S. Pervaiz
Conference closure, awards, final words, announcement of future conferences, etc
14.15 Departure of participants

List of Posters

P1 Natividad Alquezar-Artieda Prague, CZ Effect of microenvironment in the response to L-asparaginase treatment
P2 Andreja Bratovs Ljubljana, SLO Stefin A-functionalized liposomes as a system for cathepsins S and L-targeted drug delivery
P3 Eliska Davidova Prague, CZ Selective elimination of senescent cells by mitochondrial targeting is regulated via ANT2
P4 Katerina Dvorakova-Hortova Prague, CZ Transgenic mouse models as indispensable tools to study inter-cellular transfer of mitochondria
P5 Berwini Endaya Prague, CZ The mito::mKate2 transgenic mice, a novel model for mitochondrial trafficking
P6 Zuzana Ezrova Prague, CZ SMAD4 loss is associated with decreased oxidative metabolism in pancreatic cancer and affects sensitivity to mitochondrial therapy
P7 Stephanie Fliedner Prague, CZ Succinate mediates tumorigenic effects via succinate receptor 1:Potential for new targeted treatment strategies in succinate dehydrogenase-deficient paragangliomas
P8 Katerina Hlozkova Prague, CZ The role of PTEN in L-asparaginase therapy
P9 Sukanya Jadhav Prague, CZ Iron and mitochondria as targets for anti-cancer therapy
P10 Nezka Kavcic Ljubljana, SLO Cathepsin C is critical for the release of cathepsins from lysosomes in leucyl-leucine methyl ester triggered apoptosis
P11 Tomas Knedlik Padova, I Mitochondrial/peroxisomal DEPP1 as a modulator of oxidative stress-induced apoptosis
P12 Martina Koncosova Prague, CZ Effect of lactic acidosis on cancer cells treated by photodynamic therapy
P13 Zuzana Korandova Prague, CZ Molecular mechanism of pathogenesis in patients with mutation in mitochondrial RNA polymerase
P14 Martin Krkoska Brno, CZ Inhibition of Chk1 enhances cooperative anticancer action of platinum-based drugs and TRAIL via activation of mitochondrial apoptotic pathway
P15 Alenka Lovy Santiago, RCH Concerted action of AMPK and sirtuin-1 induces mitochondrial fragmentation upon bioenergetic stress caused by inhibition of Ca 2+ transfer to mitochondria
P16 Aleksandra Markovic Prague, CZ Mouse conditional knockout of Tmem70 develops liver damage and the phenotype is improved by ketogenic diet
P17 Zuzana Nahacka Prague, CZ TRAIL induces apoptosis but not necroptosis in cancer cells preferentially via the TRAIL-R2/DR5 receptor
P18 Silvia Novais Prague, CZ Oxidative phosphorylation provides stress resistance in quiescent cells
P19 Eliska Novotna Prague, CZ Mitochondrial HER2 - new role of an old oncogene
P20 Swaroop Pandey Beer-Sheva, IL SMAC/Diablo new function in regulation phospholipids synthesis in cancer cells via modulation of the mitochondrial phosphatidyl-serine decarboxylase activity
P21 Alena Pecinova Prague, CZ Metabolic phenotype and innate immune response in rat conplastic strains
P22 Dana Prukova Prague, CZ Co-targetting of BCL-2 and MCL-1 primes relapsed mantle cell lymphoma to cell death
P23 Guillermo Puertas-Frias Prague, CZ Metabolic adaptations to mitochondrial dysfunction in cellular models
P24 Daniela Simcikova Prague, CZ Hexokinase 1 is preferred but dispensable for ovarian cancer cells
P25 Caterina Vianello Padova, I Cisplatin resistance of osteosarcoma and ovarian carcinoma cells can be curtailed by blunting mitochondrial autophagy
P26 Eva Vidak Ljubljana, SLO Extracellular substrates of apoptotic caspases in cancer
P27 Michaela Vondrackova Prague, CZ Tumor suppressor NDRG1 and its regulation by iron chelators
P28 Nikola Vrzackova Prague, CZ Glutamine depletion may contribute to the therapy of solid tumors
P29 Jaroslav Zelenka Prague, CZ Lactic acidosis induces antioxidant response by Nrf2 in cancer cells: Role of mitochondrial ROS
P30 Renata Zobalova Prague, CZ Respiratory complexes III and IV drive tumour progression via dihydroorotate dehydrogenase, a potential broad-spectrum target for cancer therapy
P31 Roberto Costa Padova, I Mitochondria regulates neural crest specification and cell fate via Wnt signaling